



Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program

Marilina García^{1,2,3,4}, Maximino Redondo^{1,2,3,4}, Irene Zarcos^{2,5}, Javier Louro^{2,6}, Francisco Rivas-Ruiz^{1,2}, Teresa Téllez^{2,3,4}, Diego Pérez⁵, Francisco Medina Cano⁷, Kenza Machan⁸, Laia Domingo^{2,6}, Maria del Mar Vernet⁹, Maria Padilla-Ruiz^{1,2}, Xavier Castells^{2,6}, Maria Sala^{2,6}

¹Research Unit, Hospital Costa del Sol, Málaga, Spain

²Research Network on Health Services in Chronic Diseases (REDISSEC)

³Biomedical Research Institute of Málaga (Instituto de Investigación Biomédica de Málaga, IBIMA), Málaga, Spain

⁴Surgery, Biochemistry and Immunology Department, Medical School, University of Málaga, Málaga, Spain

⁵Department of Oncology, Hospital Costa del Sol, Marbella, Spain

⁶Department of Epidemiology and Evaluation, Hospital del Mar, Barcelona, Spain

⁷Department of Surgery, Hospital Costa del Sol, Marbella, Spain

⁸Department of Radiology, Hospital Costa del Sol, Marbella, Spain

⁹Department of Gynecology, Hospital del Mar, Barcelona, Spain

ABSTRACT

Objective: The aim of this study was to evaluate the existing survival rate and clinical-pathological differences among patients with breast cancer detected by mammographic screening.

Materials and Methods: This multicenter cohort study examined 1,248 patients who took part in a national screening program for the early detection of breast cancer over an eight-year period.

Results: Of the two patient subgroups (interval and screening), we found significant differences in the distribution of prognostic factors, with interval cases presenting at a lower mean age ($p = 0.002$), with higher percentages of human epidermal growth factor receptor 2 (HER-2) or triple negative and lower percentages of luminal A or luminal B carcinomas ($p = 0.001$), advanced stages ($p < 0.001$), lower hormone receptor expression ($p < 0.001$), poorer differentiation ($p < 0.001$) and lower survival ($p < 0.001$). Among the screening group, patients with tumors detected during the first screening round had a significantly lower mean age ($p < 0.001$), a lower frequency of comorbidities ($p = 0.038$) and a lower tendency ($p < 0.1$) to be diagnosed as triple negative breast carcinomas than incident cases.

Conclusion: Our results highlight that breast tumors detected during the first screening round are frequently characterized by a more benign phenotype than the rest of the screening subgroups, which could be of help when stratifying the risk of death and selecting the best treatment option for each patient.

Keywords: Breast cancer; risk factors; screening; survival

Cite this article as: García M, Redondo M, Zarcos I, Louro J, Rivas-Ruiz F, Téllez T, Pérez D, Cano FM, Machan K, Domingo L, Mar Vernet M, Padilla-Ruiz M, Castells X, Sala M. Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program. Eur J Breast Health 2022; 18(2): 182-189

Key Points

- Death risk may be overestimated in breast cancer patients diagnosed by screening programs when the method of detection is not considered.
- Breast cancer screening subgroups present survival and clinical-pathological differences.
- Patient risk stratification according to the screening subgroup to which they belong (prevalent, interval, incident) can help optimize their clinical management and treatment.

Introduction

The World Health Organization (WHO) has declared cancer a leading cause of death worldwide, with an estimated 9.6 million deaths in 2018. Among the different cancer types, breast cancer caused 6.6% of worldwide cancer deaths in 2018, which represents the malignancy with higher incidence (24.2%, 32.825 new cases in Spain), mortality (15%) and 5-year prevalence (30.1%) rates among women worldwide (1).

According to the WHO, early detection is critical to improve breast cancer outcomes and survival. In this regard, despite selection, lead-time, length and overdiagnosis biases (2), the increasing implementation of screening programs has allowed for early patient diagnosis, quick treatment and an increased chance for successful treatment that can reduce mortality rates by up to 20% (3). For this reason, and despite reported handicaps of screening programs, such as high costs or derived risk from ionizing radiation, breast self-examination and other clinical explorations including mammography or ultrasonography represent the main tools for early diagnosis and timely treatment to lessen breast cancer morbidity. Indeed, although mammography screenings are not precise predictors of outcome (4) because of their inability to discriminate between malignant and benign breast masses, these programs along with histopathology studies have proven useful in significantly reducing mortality in women receiving adequate follow-up (5).

In some countries, breast cancer age-standardized mortality rates have decreased by 2%–4% per year since the 1990s, but others have yet to achieve this outcome, as countries with low breast cancer mortality rates are characterized by increased levels of essential health services coverage and higher numbers of public cancer centers (6). There is evidence that two thirds of all women with breast cancer are still diagnosed after presenting to their clinicians with symptoms and not through screening (7).

Contrary to these symptomatic tumors usually characterized by a fast development, growth and spread, breast screening normally detects a higher proportion of slow-growing tumors, that can even remain unnoticed in a woman's lifetime (4, 8-10), which are associated with a better prognosis than tumors of similar size found outside patient screening (11-14). In addition to differences in growth rate, the survival advantage of these cases may also be due to additional biological differences, such as hormone receptors expression or human epidermal growth factor receptor 2 (HER-2) status, among others (13, 15, 16). Studies also show agreement that screening-detected breast cancers have relatively better tumor prognostic characteristics, biomarker profile and survival outcomes than those tumors diagnosed between two screenings (17, 18), also known as interval tumors.

On the other hand, although the epidemiology, radiological and biological characteristics of interval breast cancers versus population mammography-detected screening tumors is well documented (17, 19, 20), the prognostic and biological differences between screening-detected breast cancer subtypes, namely prevalent tumors, when diagnosed in the first screening round, or incident tumors when diagnosed in successive screening rounds, still need to be clarified. In this regard, a previous study from our research group reported

significant differences between prevalent and incident tumors, showing that prevalent breast tumor cases present more favorable biologic and prognostic features than incident cases (21).

Despite the potential clinical benefit that these biological and clinical-pathological differences could have when selecting the most appropriate treatment and care methods for breast cancer patients, they are not considered in common Clinical Practice Guidelines. For this reason, and as a continuation of our previous investigations, in the present study we will evaluate if there are sociodemographic, clinical and biologic differences between prevalent, incident and interval breast cancer cases and their association with patient overall survival in a large cohort of healthy Spanish women participating in breast cancer screening programs.

Materials and Methods

Study Design

We conducted an analytical study to evaluate the differences between breast cancer tumors detected during a screening test (prevalent and incident cases) and those detected in women after a negative screening test and before the next screening invitation (interval cases) (n = 1,086). We also evaluated the differences between prevalent and incident cases among screen-detected cases (n = 741). In addition, we performed a survival study to evaluate the impact of the detection process (screen-detected cancer vs. interval breast cancer) on global survival.

Patients and samples

This observational study included 1,086 women aged 45–69 years, with no known risk factors associated with breast cancer, who had participated in a screening program supported by four national breast-cancer screening programs which provide biannual mammograms and annual examinations for women with clinical indications of increased risk. This nationwide program meets the required standards (22). The diagnoses and surgical interventions all took place during the period 2000–2008, with follow up until 2014.

Variables

- Biologic characteristics: Phenotype (Luminal A, Luminal B, HER-2, Triple Negative), Stage (*in situ*, Stage I, Stage II, Stage III), Estrogen Receptor Expression (positive, negative), progesterone receptor expression (positive, negative), HER-2 receptor enrichment (positive, negative), Ki-67 score (<14%, >14%), tumor grade (Grade I, Grade II, Grade III), Death (yes, no).
- Patient clinical history: Associated diseases required to calculate the Charlston Comorbidity Index (CCI): myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic lung disease, connective tissue pathology, ulcerative disease, mild/moderate/severe hepatic disease, diabetes, diabetes with organic lesion, hemiplegia, renal pathology (moderate/severe), solid neoplasms, leukemia, malignant lymphoma, solid metastasis, and/or AIDS.
- Survival.
- Patient: age, family history.

Scope

Data were obtained from the multicenter retrospective cohort of women CAMISS (ClinicalTrials.gov Identifier: NCT03165006) that included 1,086 women with breast cancer participating in a population-based screening program in which three public hospitals, belonging to the Spanish National Health Service, in three Spanish regions (Andalusia, Canary Islands, Catalonia) were involved. The main objective of the CAMISS-retrospective study was to evaluate the impact of the diagnosis process (screen-detected cancer vs. interval breast cancer) on overall survival (23).

Statistical Analysis

Univariate Analysis

Descriptive analysis segmented by the type of diagnosis (interval *versus* screening and prevalent *versus* incident). Comparison of the mean was performed by the Student’s t-test after confirming the normal distribution of the quantitative variable and homogeneity of the variance, while comparison of frequencies was made by the chi-square test or by the Fisher’s test when categories have expected frequencies less than 5 in more than 20% of cases.

Survival Analysis

Survival analysis was performed using the Kaplan–Meier method to compare the types of diagnosis. In addition, Cox regression analysis was applied to estimate the risk of death and adjusted with entry criteria for the following variables: age, comorbidity (presence, absence), and tumor stage (*in situ*, Stage I, Stage II, Stage III). The relative risk and the corresponding 95% confidence interval were calculated. In the survival study, the primary endpoint was time elapsed to death from breast cancer from the time of diagnosis. Survival times for patients who were still alive were assumed to be the last date of follow-up. Patients who were still alive at the closing date were censored.

Results

We segmented and compared patient data for interval and screening breast cancer (incident and prevalent). The univariate analysis showed significant differences, with screening cases presenting at a higher mean ± standard deviation age of 58.8±5.5 years than interval cases 57.7±5.3 years ($p = 0.002$), as well as with a higher frequency of hormone receptors expression ($p<0.001$) and luminal A and luminal B phenotypes ($p = 0.001$). Screening tumors also presented with a significantly different phenotype, with a lower frequency of triple negative tumors ($p = 0.001$), less advanced stage ($p<0.001$) and lower grade ($p<0.001$) and fewer deaths ($p<0.001$). We also found a tendency ($p<0.1$) for screening cases to have a family history of breast cancer more frequently than interval cases. We did not find any significant differences for comorbidity, Charlson Index, HER-2 enrichment or Ki-67 expression variables (Table 1).

The improved survival of screening cases is also evident in both the survival function (Figure 1) and the multivariate Cox regression analysis, in which interval cases [hazard ratio (HR): 1.63, confidence interval (CI) = 1.13–2.36; $p = 0.01$] as well as the presence of comorbidity (HR: 1.48, CI = 1.05–2.10; $p = 0.03$) and advanced stage (HR: 4.82, CI = 1.17–19.80 for stage I; HR: 4.96, CI = 1.19–20.62 for stage II and HR: 16.25, CI = 3.89–67.77 for stage III; $p<0.001$) were associated with an increased risk of death (Table 2).

We also found significant differences between prevalent and incident cases. In this situation, patients with prevalent tumors presented at a lower mean age ($p<0.001$), with a lower frequency of comorbidity ($p = 0.038$) and a tendency ($p = 0.051$) to be diagnosed as triple negative less frequently. We did not find significant differences for the rest of the variables studied (Table 3).




Figure 1. Overall survival curve (Kaplan–Meier) for interval and screening cases. Compared to interval cases, the Kaplan–Meier analysis shows improved survival of screening cases. Number of cases is 1,086, 158 deaths and 4,657 days as median follow-up time for both groups. Hazard ratio (HR): 2.53 [confidence interval (CI): 95%: 1.84-3.46] and $p<0.001$ from a univariate Cox model

Table 1. Sociodemographic and clinical characteristics of patients with interval and screening breast cancer

Variables	Interval (n = 345)		Screening (n = 741)		p-value
	n	%	n	%	
Age at diagnosis					
Mean ± SD	57.7	5.3	58.8	5.5	0.002**
Comorbidity					
Absence	254	73.6	534	72.1	0.643
Presence	91	26.4	207	27.9	
Charlson Index					
Mean ± SD	0.79	1.60	0.76	1.56	0.78
Family history¹					
No	201	90.5	519	85.8	0.091
Yes	21	9.5	86	14.2	
Phenotype²					
Luminal A	140	45.9	278	56.9	0.001***
Luminal B	82	26.9	133	27.2	
HER-2	33	10.8	38	7.8	
TNBC	50	16.4	40	8.2	
Stage³					
<i>In situ</i>	14	4.2	88	12.2	<0.001***
I	88	26.6	385	53.3	
II	144	43.5	199	27.5	
III	85	25.7	51	7.1	
Estrogen receptors					
Negative	97	28.1	127	17.1	<0.001***
Positive	248	71.9	614	82.9	
Progesterone receptors⁴					
Negative	147	42.7	233	31.5	<0.001
Positive	197	57.3	507	68.5	
HER-2⁵					
Negative	242	77.6	401	79.9	0.484
Positive	70	22.4	101	20.1	
Ki-67 expression					
<14%	107	53.2	103	45	0.107
>14%	94	46.8	126	55	
Grade⁷					
I	51	17.9	183	31.1	<0.001***
II	107	37.5	252	42.9	
III	127	44.6	153	26	

Missing data: ¹ = 259, ² = 292, ³ = 32, ⁴ = 2, ⁵ = 272, ⁶ = 656, ⁷ = 213.

Very significant; *Highly significant

TNBC: triple negative breast cancer; HER-2: human epidermal growth factor receptor 2; SD: standard deviation; n: number

Table 2. Factors related to overall mortality by Cox regression analysis: screening and interval cases

Risk factor	p-value	HR	CI 95%	
			Lower	Upper
Type of diagnosis				
Screening	0.01	1.00		
Interval		1.63	1.13	2.36
Age	0.15	1.02	0.99	1.06
Comorbidity				
Absence	0.03	1.00		
Presence		1.48	1.05	2.10
Stage				
<i>In situ</i>		1.00		
I	<0.001	4.82	1.17	19.80
II		4.96	1.19	20.62
III		16.25	3.89	67.77

HR: hazard ratio; CI: confidence interval

The multivariate analysis showed an increased risk of death for advanced stages (HR: 3.88, CI = 0.94–16.10 for stage I; HR: 3.26, CI = 0.75–14.18 for stage II and HR: 15.69, CI = 3.62–68.12 for stage III; $p < 0.001$) and also revealed a similar behavior in survival numbers for both cancer subgroups (Table 4).

Discussion and Conclusion

Our study of a large series of screening-detected breast carcinomas shows that not only variables which are generally associated with a less aggressive behavior and a better prognosis are more frequent in screening tumors than in interval tumors but also that, among screening tumors, prevalent cases exhibit the most favorable prognostic factors. Specifically, our study shows the existence of a number of biological and clinical-pathological features among screening-detected breast tumors subtypes which reinforce the idea that the method of detection should be considered in risk estimations and avoid the use of aggressive treatments in those cases with a more favorable prognosis, such as breast cancer patients with prevalent tumors.

Consistent with other published studies reporting that the risk of distant metastases can be overestimated for breast cancer patients diagnosed by mammography screening unless the method of detection (mammography screening or other methods) is taken into account in the risk estimation (11), our results show that the method of detection can be considered as a prognostic factor for breast cancer patients, even after adjusting for known tumor characteristics (12, 24, 25) possibly due to differences in tumor features and biology (13, 20, 26, 27). Specifically, we reveal that, compared to interval tumors, screening-detected breast tumors present with less aggressive biological characteristics and more favorable prognostic features, such as low-grade, early-stage, expression of hormone receptors and Luminal A or

Luminal B phenotypes, improved survival, and lower mean age as well as a tendency to have a higher frequency of cancer family history. Our results are in keeping with previous studies from our research group (28). These observed that screening cases showed different biological characteristics that are generally associated with reduced tumor aggressiveness and enhanced survival, such as positive expression of hormone receptors. Accordingly, interval cases are characterized by more-aggressive tumor characteristics and poorer survival outcomes (18, 20, 29) than screening-detected cases, despite receiving more adjuvant chemotherapy (28, 30).

Altogether, our results would support the need for cancer trialists to routinely collect information about method of detection when determining risk estimations (12) and the potential utility of considering the time of diagnosis within a breast screening program during decision-making on the best treatment strategy for the patient.

We also studied if there were any clinical or prognostic differences between prevalent and incident screening groups. We observed that prevalent tumors were characterized by some features, such as lower mean patient age, lower frequency of comorbidity and have a tendency to be diagnosed as triple negative less frequently (Table 2), generally associated with a better prognosis. Although a previous study from our group in a different cohort also found an association with an improved survival for prevalent screen-detected breast tumors (21), we did not find this survival advantage over incident tumors in this series, which would justify further studies with additional patient cohorts. Despite these contradictory results, considering that the prognosis of prevalent cases would not be affected by the use of adjuvant chemotherapy (28), tumor trialists should routinely collect information about method of detection (12), since the inclusion of the type of screening-detected breast cancer subgroup in clinical practice guidelines could help provide patients with the best care options.

Table 3. Sociodemographic and clinical characteristics of patients with prevalent and incident breast cancer

Variables	Prevalent (n = 188)		Incident (n = 553)		p-value
	n	%	n	%	
Age					
Mean ± SD	54.3	4.9	60.3	4.8	<0.001***
Comorbidity					
Absence	147	78.2	387	70	0.038*
Presence	41	21.8	166	30	
Charlson Index					
Mean ± SD	0.62	1.46	0,81	1.59	0.161
Family history¹					
No	132	87.4	387	85.2	0.597
Yes	19	12.6	67	14.8	
Phenotype²					
Luminal A	60	60.0	218	56.0	0.051
Luminal B	27	27.0	106	27.2	
HER-2	11	11.0	27	6.9	
TNBC	2	2.0	38	9.8	
Stage³					
<i>In situ</i>	26	14.4	62	11.4	0.725
I	92	50.8	293	54.1	
II	51	28.2	148	27.3	
III	12	6.6	39	7.2	
Estrogen receptors					
Negative	32	17.0	95	17.2	1
Positive	156	83.0	458	82.8	
Progesterone receptors⁴					
Negative	50	26.6	183	33.2	0.114
Positive	138	73.4	369	66.8	
HER-2⁵					
Negative	78	77.2	323	80.5	0.545
Positive	23	22.8	78	19.5	
Ki-67 expression					
<14%	28	48.3	75	43.9	0.666
>14%	30	51.7	96	56.1	
Grade⁷					
I	48	34.8	135	30.0	0.199
II	62	44.9	190	42.2	
III	28	20.3	125	27.8	

*Significant; ***Highly significant

Missing data: ¹ = 259; ² = 292; ³ = 32; ⁴ = 2; ⁵ = 272; ⁶ = 656; ⁷ = 213

TNBC: triple negative breast cancer; HER-2: human epidermal growth factor receptor 2; SD: standard deviation; n: number

Table 4. Factors related to overall mortality by Cox regression analysis: prevalent and incident cases

Risk factor	β	p-value	HR	CI 95%	
				Lower	Upper
Type of diagnosis					
Prevalent			1.00		
Incident	0.01	0.98	1.01	0.56	1.81
Age	0.04	0.10	1.04	0.99	1.09
Comorbidity					
Absence			1.00		
Presence	0.18	0.46	1.20	0.73	1.97
Stage					
<i>In situ</i>			1.00		
I	1.36		3.88	0.94	16.10
II	1.18	<0.001	3.26	0.75	14.18
III	2.75		15.69	3.62	68.12

HR: hazard ratio; CI: confidence interval

In conclusion, our results show that risk factors may be overestimated for breast cancer patients diagnosed by screening programs when the method of detection is not considered. Furthermore, our results suggest a need to continue investigating patient survival and clinical-pathological differences between breast tumors detected by screening, highlighting the potential benefit that patient risk stratification according to the screening subgroup to which they belong (prevalent, interval, incident) can have to optimize their clinical management and treatment.

Acknowledgments

The authors are grateful to María del Carmen Delgado Navarro for her excellent technical assistance.

Ethics Committee Approval: This study was approved by Costa del Sol Hospital Ethics Committee (decision/file number: 003-Nov-PR2, date: 24.11.2016).

Informed Consent: It was obtained.

Peer-review: Externally peer-reviewed.

Author Contributions

Concept: M.G., X.C., M.S., M.R.; Methodology: I.Z., T.T., D.P., F.M.C., K.M., L.D., M.M.V., M.P.R.; Analysis and/or Interpretation: J.L., F.R.R.; Writing: M.G., M.R., M.S.; Funding acquisition: M.R.; Supervision: M.R.

Conflict of Interest: The authors declare no conflict of interest.

Financial Disclosure: This research was partially supported by grants from REDISSEC (RD12/0001/0010 and RD16/0001/0006), RICAPPS (RD21/0016/0015), Consejería de Salud Junta de Andalucía (PI 16/0298) and the European Regional Development Fund. The researcher Marilina García-Aranda is the benefactor of a postdoctoral contract financed by the European Social Fund - Operational Program of Andalusia 2014-2020 for the

"Incorporation of Research Personnel with a PhD degree in the field of Health Sciences and Technologies in R&D and Innovation Centers of the Public Health System of Andalusia" (RH-0055-2020).

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2020; 70: 313. (PMID: 32767693) [\[Crossref\]](#)
- Moller H, Davies E. Over-diagnosis in breast cancer screening. *BMJ* 2006; 332: 691-692. (PMID: 16517549) [\[Crossref\]](#)
- Shah TA, Guraya SS. Breast cancer screening programs: Review of merits, demerits, and recent recommendations practiced across the world. *J Microsc Ultrastruct* 2017; 5: 59-69. (PMID: 30023238) [\[Crossref\]](#)
- Day NE. Overdiagnosis and breast cancer screening. *Breast Cancer Res* 2005; 7: 228-229. (PMID: 16168144) [\[Crossref\]](#)
- Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen* 2012; 19(Suppl 1): 14-25. (PMID: 22972807) [\[Crossref\]](#)
- Duggan C, Trapani D, Ilbawi AM, Fidarova E, Laversanne M, Curigliano G, et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. *Lancet Oncol* 2021; 22: 1632-1642 (PMID: 34653370) [\[Crossref\]](#)
- Lyratzopoulos G, Abel G. Earlier diagnosis of breast cancer: focusing on symptomatic women. *Nat Rev Clin Oncol* 2013; 10. (PMID: 23881030)
- Donzelli A. The benefits and harms of breast cancer screening. *Lancet* 2013; 381: 799-800. (PMID: 23668504) [\[Crossref\]](#)
- Dillon MF, Hill AD, Quinn CM, O'Doherty A, Crown J, Fleming FJ, et al. Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer. *J Med Screen* 2004; 11: 130-134. (PMID: 15333271) [\[Crossref\]](#)

10. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? *Ann Intern Med* 1997; 127: 1023-1028. (PMID: 9412284) [\[Crossref\]](#)
11. Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. *JAMA* 2004; 292: 1064-1073. (PMID: 15339900) [\[Crossref\]](#)
12. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. *J Natl Cancer Inst* 2005; 97: 1195-1203. (PMID: 16106024) [\[Crossref\]](#)
13. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? *Br J Cancer* 2008; 98: 1741-1744. (PMID: 18506175) [\[Crossref\]](#)
14. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. *Br J Cancer*. 2009;101(8):1338-1344. (PMID: 19773756) [\[Crossref\]](#)
15. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 1108-1112. (PMID: 15894660) [\[Crossref\]](#)
16. Musolino A, Michiara M, Conti GM, Boggiani D, Zatelli M, Palleschi D, et al. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study. *J Clin Oncol* 2012; 30: 2362-2368. (PMID: 22585698) [\[Crossref\]](#)
17. Houssami N, Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. *NPJ Breast Cancer* 2017; 3: 12. (PMID: 28649652) [\[Crossref\]](#)
18. Grassmann F, He W, Eriksson M, Gabrielson M, Hall P, Czene K. Interval breast cancer is associated with other types of tumors. *Nat Commun* 2019; 10: 4648. (PMID: 31641120) [\[Crossref\]](#)
19. Domingo L, Salas D, Zubizarreta R, Baré M, Sarriugarte G, Barata T, et al. Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. *Breast Cancer Res* 2014; 16: R3. (PMID: 24410848) [\[Crossref\]](#)
20. Irvin VL, Zhang Z, Simon MS, Chlebowski RT, Luoh SW, Shadyab AH, et al. Comparison of Mortality Among Participants of Women’s Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers. *JAMA Netw Open* 2020; 3: e207227. (PMID: 32602908) [\[Crossref\]](#)
21. Redondo M, Funez R, Medina-Cano F, Rodrigo I, Acebal M, Tellez T, et al. Detection methods predict differences in biology and survival in breast cancer patients. *BMC Cancer* 2012; 12: 604. (PMID: 23244222) [\[Crossref\]](#)
22. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, et al. Cancer screening in Spain. *Ann Oncol* 2010; 21(Suppl 3): iii43-51. (PMID: 20427360) [\[Crossref\]](#)
23. García-Gutierrez S, Orive M, Sarasqueta C, Legarreta MJ, Gonzalez N, Redondo M, et al. Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study. *BMC Cancer* 2018; 18: 54. (PMID: 29310641) [\[Crossref\]](#)
24. Puvanesarajah S, Gapstur SM, Patel AV, Sherman ME, Flanders WD, Gansler T, et al. Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II. *Breast Cancer Res Treat* 2019; 177: 679-689. (PMID: 31264062) [\[Crossref\]](#)
25. Shen SC, Ueng SH, Yang CK, Yu CC, Lo YF, Chang HK, et al. Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a, bN0 Breast Cancer. *J Cancer* 2017; 8: 2328-2335. (PMID: 28819437) [\[Crossref\]](#)
26. Caldarella A, Puliti D, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. *J Cancer Res Clin Oncol* 2013; 139: 181-185. (PMID: 22961208) [\[Crossref\]](#)
27. Kirsh VA, Chiarelli AM, Edwards SA, O’Malley FB, Shumak RS, Yaffe MJ, et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. *J Natl Cancer Inst* 2011; 103: 942-950. (PMID: 21540443) [\[Crossref\]](#)
28. Zarcos-Pedrinaci I, Redondo M, Louro J, Rivas-Ruiz F, Téllez T, Pérez D, et al. Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. *Cancer Med* 2019; 8: 6662-6670. (PMID: 31549794) [\[Crossref\]](#)
29. Bellio G, Marion R, Giudici F, Kus S, Tonutti M, Zanconati F, et al. Interval breast cancer versus screen-detected cancer: comparison of clinicopathologic characteristics in a single-center analysis. *Clin Breast Cancer* 2017; 17: 564-571. (PMID: 28456487) [\[Crossref\]](#)
30. Rayson D, Payne JI, Abdoell M, Barnes PJ, MacIntosh RF, Foley T, et al. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. *Clin Breast Cancer* 2011; 11: 27-32. (PMID: 21421519) [\[Crossref\]](#)